Eilon Kirson

Eilon Kirson led the pivotal clinical development of TTFields from bench to bedside, directing the EF-11 and EF-14 trials that established TTFields as standard of care for newly diagnosed glioblastoma with a significant overall survival benefit when combined with temozolomide. His work on TTFields dosimetry and treatment compliance metrics demonstrated the dose-response relationship between daily usage hours and survival outcomes. He continues to advance TTFields combination strategies with immunotherapy and targeted agents across multiple tumor types.